

**Advancing Animal Models for Antibacterial Drug Development –**

**March 5, 2020**

**Speakers and Panelists**

**Jürgen Bulitta, Ph.D.**

Associate Professor  
College of Pharmacy  
University of Florida  
Gainesville, FL

**Cara Cassino, MD**

Chief Medical Officer  
Executive VP of Research and Development  
ContraFect  
Yonkers, NY

**Binh Diep, Ph.D.**

Associate Professor, Medicine  
University of California, San Francisco  
San Francisco, CA

**John Farley, MD, MPH**

Director (Acting)  
Office of Infectious Diseases (OID)  
FDA/CDER/OND  
Silver Spring, MD

**Tina Guina, Ph.D**

CARB-X Program Manager  
Biomedical Advanced Research and Development Authority (BARDA)  
Office of the Assistant Secretary for Preparedness and Response (ASPR)  
Department of Health and Human Services (HHS)  
Washington, D.C.

**Judith Hewitt, Ph.D**

Deputy Director  
Office of Biodefense, Research Resources, and Translational Research  
NIH/National Institute of Allergy and Infectious Diseases (NIAID)  
Rockville, MD

**Jennifer Hoover**

Scientific Director  
Medicine Opportunities Research Unit  
GlaxoSmithKline  
Collegeville, PA

**William Hope, BMBS, Ph.D**

Chair of AMR Research  
Director of Centre of Excellence in Infectious Disease Research  
Professor, Molecular and Clinical Pharmacology, University of Liverpool  
Liverpool, UK

**Abhay Joshi, Ph.D**

Pharmacology Reviewer  
Division of Infectious Disease Pharmacology (DIDP)  
Office of Clinical Pharmacology (OCP)  
FDA/CDER/OTS  
Silver Spring, MD

**Marina Kozak, Ph.D.**

Biologist  
Division of CBRN Countermeasures  
HHS/ASPR/BARDA  
Washington, D.C

**Matthew Lawrenz, Ph.D**

Associate Professor  
Dept. of Microbiology & Immunology  
University of Louisville  
Louisville, KY

**Alexander Lepak, MD**

Assistant Professor of Medicine  
Dept. of Medicine  
University of Wisconsin – Madison  
Madison, WI

**Brian Luna, Ph.D**

Assistant Professor of Molecular Biology and Immunology  
Keck School of Medicine  
University of Southern California  
Los Angeles, CA

**Lynn Miesel, Ph.D**

Global Technical Director  
In-Vivo Pharmacology  
Pharmacology Discovery Services Ltd., Eurofins Panlabs, Inc.  
New York, NY

**Sumathi Nambiar, MD, MPH**

Director  
Division of Anti-Infectives (DAI)  
FDA/CDER/OND/OID  
Silver Spring, MD

**Eric Nuermberger, MD**

Associate Professor  
School of Medicine  
Johns Hopkins University  
Baltimore, MD

**Andrew Phipps, DVM, Ph.D, DACVM**

Subject Matter Expert, Contractor  
Tunnell Government Services – Supporting Division of CBRN Countermeasures  
HHS/ASPR/BARDA  
Washington, D.C.

**Kellie Reynolds, Ph.D**

Director  
Division of Infectious Disease Pharmacology (DIDP)  
FDA/CDER/OTS/OCP  
Silver Spring, MD

**Simone Shurland, Ph.D**

Microbiology Reviewer  
DAI  
FDA/CDER/OND  
Silver Spring, MD

**Bradley Spellberg, MD**

Chief Medical Officer, Los Angeles County-University of Southern California Medical Center  
Medical Director of Biosciences, Los Angeles, CA  
Associate Dean for Clinical Affairs, Keck School of Medicine, USC  
Los Angeles, CA

**Ursula Waack, MS, Ph.D**

Oak Ridge Institute for Science and Education (ORISE) Fellow  
OID  
FDA/CDER/OND  
Silver Spring, MD

**Achim Wach, Ph.D**

Head DMPK/TK  
Polyphor Ltd.  
Allschwil, Switzerland

**Thomas Walsh, MD, Ph.D.**

Chief, Infectious Diseases Translational Research Laboratory  
Professor of Medicine  
Weill Cornell Medicine of Cornell University  
New York, NY

**Edward Weinstein, MD, Ph.D**

Lead Medical Officer  
DAI  
FDA/CDER/OND/OID  
Silver Spring, MD

**William Weiss, MS**

Director, Preclinical Services  
College of Pharmacy  
University of North Texas Health Science Center  
Fort Worth, TX

**Yuliya Yasinskaya, MD**

Lead Medical Officer  
DAI  
FDA/CDER/OND/OID  
Silver Spring, MD

## **Disclosures**

**Jürgen Bulitta** received funding from NIH and FDA. Has performed consultant services for MicuRx.

**Cara Cassino** is a full time employee of ContraFect Corporation.

**Binh Diep** received research funding from NIH/NIAID, US Food and Drug Administration, Department of Defense DARPA, CARB-X, as well as Achaogen, Arsanis, AstraZeneca/MedImmune, Roche/Genentech, Integrated Biotherapeutics, Merck/Cubist, and Pfizer.

**Jennifer Hoover** is a full-time employee and shareholder of GlaxoSmithKline Pharmaceuticals.

**William Hope** holds or has recently held research grants with F2G, Astellas Pharma, Spero Therapeutics, Antabio, Allecra, Bugworks, and NAEJA-RGM. He holds awards from the Medical Research Council, National Institute of Health Research, FDA and the European Commission. William Hope has received personal fees in his capacity as a consultant for F2G, Amplyx, Ausperix, Spero Therapeutics, VenatoRx, Pfizer and BLC/TAZ.

**Matthew Lawrenz** is a full time employee of the University of Louisville. He receives funding support from NIH and FDA.

**Alexander Lepak** currently receives grant funding from NIH, Merck & Co., Inc, and MicuRx Pharmaceuticals, Inc.

**Brian Luna** owns equity in ExBaq.

**Lynn Miesel** is an employee of Eurofins Scientific.

**Eric Nuermberger** has no disclosures

**Brad Spellberg** has received consulting fees from Merck, Shionogi, Acurx, and Klaris, and owned equity in BioAIM, ExBaq, Mycomed, and Motif in the past year.

**Achim Wach** is a full time employee of Polyphor Ltd. He is also a shareholder of the company

**Thomas Walsh** has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediand, Medicines Company, Merck, Scynexis, and Tetrphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Lediand, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.

**William Weiss** is a full time employee of the UNT System College of Pharmacy, a consultant for Aptorum Therapeutics and has performed sponsor funded research for ABAC Therapeutics, Achaogen, Achillion, Adenium, Affinium, Agile, Akthelia, Alcon, AmpliPhi, Amplyx, Anacor, Appili, Arietis, Arrevis, Astra Zeneca, AtoxBio, Aurasense, Auspherix, AyuVis, AzuRx, Basilea, Biolytix, BioPharmaTi, Biota, Bisortia, Biosynexus, Bioversys, Bioiness, Cantab, Cartledge Growth, Case Western, Cidara, Contrafect, Cubist, CUBRC, Curza, DaVolterra, DeNovaMed, DuoPhos, Entasis, eTherapeutics, Exarca, Facile Therapeutics, FCCDC, Fedora, FOB synthesis, Forge Therapeutics, Gen3Immune, Genentech, Gilead, Gladius, Gradalis, Grifols, GSK, Harvard University, InhibRx, Insmad, Janssen, Kaleido, Kalyra, Lakewood Amedex, Lead Therapeutics, LegoChem, LipoMedics, Lily Pharmaceuticals, Locus Biosciences, Macrolide Pharma, Matinas, Matrivax, MedImmune, Melinta, Merck, Merlion, Microeos, Microbion, Mpex, Mutabilis, Nabiva, National Institute of Biotechnology Negev, NCSU, Nimbus, Novabiotics, Novacta, Novartis, Novoxel, Novostar, Novozymes, Octagon, Omm Scientific, OncoNano, Oragenics, Ordway, Peptilogics, Pharmaxis, Polymedix, Polyphor, Prolysis, Purdue University, Reata, RemPex, RQx Pharmaceuticals, Secretory IgA, Seres Therapeutics, Spero Therapeutics, Stanford School of Medicine, St. Judes, Summit, Synermore, Global TB Alliance, Techulon, TenNor, Tetrphase, Thar, Theravance, Trius, UCSF, UNMC, University of Bern, Venatorx, Ventria, Vical, VicLink, Visterra, Wockhardt, Zavante, ZSPharma